Immuron Receives $1.6M R&D Tax Concession Refund
Filed with ASX · · 1 page · English
In the deck
Story so far
Earlier from Immuron
- Immurons NASH Phase II Trial Achieves 100 Patient Milestone
- NASH Phase II Trial reaches 75% of Patient Recruitment
- Immurons $6M Rights Issue Closes Oversubscribed
- Appendix 4E and Annual Report
- Immuron Expands Collaborate with US Navy
Later from Immuron
- NASH MOA Study commences with SanyalBio & Duke University
- First Patient in Pediatric Fatty-Liver Phase II Trial
- Immuron Completes Phase II NASH Clinical Trial Recruitment
- Appendix 4D - Half Year Report and Accounts - Dec 2016
- Close of Recruitment of Phase II NASH Trial
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron